Pharmaceutical Having around a year ago issued a refuse to file letter (The Pharma Letter April 5, 2011), the US Food and Drug Administration has accepted for review global drugs behemoth Pfizer's (NYSE: PFE) New Drug Application for tafamidis meglumine, the company's investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). 16 February 2012